

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 4 OCT 03 MATHDI removed from STN  
NEWS 5 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added  
to core patent offices  
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005  
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download  
of CAPLUS documents for use in third-party analysis and  
visualization tools  
NEWS 8 OCT 27 Free KWIC format extended in full-text databases  
NEWS 9 OCT 27 DIOGENES content streamlined  
NEWS 10 OCT 27 EPFULL enhanced with additional content  
NEWS 11 NOV 14 CA/CAPLUS - Expanded coverage of German academic research  
  
NEWS EXPRESS NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.  
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:13:26 ON 29 NOV 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:13:54 ON 29 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2005 HIGHEST RN 868827-82-1  
DICTIONARY FILE UPDATES: 28 NOV 2005 HIGHEST RN 868827-82-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "M-THPC"/CN 25

E1	1	M-THIOCRESOL/CN
E2	1	M-THIZONE/CN
E3	0 -->	M-THPC/CN
E4	1	M-THYMOL/CN
E5	1	M-THYMOL, 2,2'-(P-METHOXYBENZYLIDENE) DI-/CN
E6	1	M-THYMYL TRICHLOROACETATE/CN
E7	1	M-TMI/CN
E8	1	M-TMXDI/CN
E9	1	M-TMXDU/CN
E10	1	M-TOIN/CN
E11	1	M-TOLIDINE/CN
E12	1	M-TOLIDINE, A,A,A,A',A',A'-HEXAFLUORO-/CN
E13	1	M-TOLIDINE, A,A,A,A',A',A'-HEXAFLUORO-, DITARTRATE/CN
E14	1	M-TOLIDINE, 5-NITRO-/CN
E15	1	M-TOLIDINE, 6,6'-DICHLORO-N,N'-DICINNAMYLIDENE-/CN
E16	1	M-TOLIDINE, COMPD. WITH BUOH/CN
E17	1	M-TOLIDINE, COMPD. WITH FEI2/CN
E18	1	M-TOLIDINE, N-ACETOACETYL-N'-ACETYL-/CN
E19	1	M-TOLIDINE-PYROMELLITIC DIANHYDRIDE COPOLYMER/CN
E20	1	M-TOLIL/CN
E21	1	M-TOLIL, 4,4'-DIETHOXY-/CN
E22	1	M-TOLIL, 4,4'-DIMETHOXY-/CN
E23	1	M-TOLIL, 5,5'-DIETHOXY-4,4'-DIHYDROXY-A,A'-DIMORPHOLINO-/CN
E24	1	M-TOLIL, 5,5'-DIETHOXY-4,4'-DIHYDROXY-A,A'-DIPERIDINO-/CN
E25	1	M-TOLIL, 6,6'-DIMETHOXY-/CN

=> E "THPC"/CN 25

E1	1	THP-ADRIAMYCIN HCL/CN
E2	1	THP-M/CN

E3 1 --> THPC/CN  
 E4 1 THPE/CN  
 E5 1 THPO/CN  
 E6 1 THPO PROTEIN (MOUSE STRAIN FVB/N CLONE MGC:6080 IMAGE:3593885)/CN  
 E7 1 THPOH/CN  
 E8 1 THPOH, POLYMER WITH 1,2-ETHANEDIAMINE/CN  
 E9 1 THPOH, POLYMER WITH 1,3-DICHLORO-2-PROPANOL AND UREA/CN  
 E10 1 THPOH, POLYMER WITH 1,6-HEXANEDIAMINE/CN  
 E11 1 THPOH, POLYMER WITH 3-BROMOPHENOL, 1,2-ETHANEDIAMINE AND  
 FORMALDEHYDE/CN  
 E12 1 THPOH, POLYMER WITH 4-BROMOPHENOL, 1,2-ETHANEDIAMINE,  
 FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E13 1 THPOH, POLYMER WITH 4-BROMOPHENOL, 1,2-ETHANEDIAMINE,  
 FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT),  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM HYDROXIDE AND TETRAKIS(HYDROXYMETHYL)PHOSPHONI/CN  
 E14 1 THPOH, POLYMER WITH AMMONIA/CN  
 E15 1 THPOH, POLYMER WITH AMMONIA, 3-BROMOPHENOL AND FORMALDEHYDE/CN  
 E16 1 THPOH, POLYMER WITH AMMONIA, 3-BROMOPHENOL, FORMALDEHYDE,  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E17 1 THPOH, POLYMER WITH AMMONIA, FORMALDEHYDE AND PHENOL/CN  
 E18 1 THPOH, POLYMER WITH AMMONIA, FORMALDEHYDE, PHENOL,  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E19 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE ((NH4)(OH)),  
 3-BROMOPHENOL, FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E20 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE ((NH4)(OH)),  
 FORMALDEHYDE, PHENOL, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E21 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE, 3-BROMOPHENOL,  
 FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E22 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE, FORMALDEHYDE, PHENOL,  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E23 1 THPOH, POLYMER WITH FORMALDEHYDE, PHENOL AND  
 1,3,5,7-TETRAAZATRICYCLO(3.3.1.1<sup>3,7</sup>)DECANE/CN  
 E24 1 THPOH, POLYMER WITH UREA/CN  
 E25 1 THPOH-NH3/CN

=> S E3

L1 1 THPC/CN

=> DIS L1 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS  
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 124-64-1 REGISTRY

CN Phosphonium, tetrakis(hydroxymethyl)-, chloride (8CI, 9CI) (CA INDEX  
 NAME)

OTHER CA INDEX NAMES:

CN Tetrakis(hydroxymethyl)phosphonium chloride (6CI)

OTHER NAMES:

CN NSC 30698

CN Pyroset TKC

CN Tetrahydroxymethylphosphonium chloride

CN Tetrakis(hydroxymethyl)phosphochloride


CN Tetramethylolphosphonium chloride

CN THPC

AR 16980-25-9

DR 2245-60-5

MF C4 H12 O4 P . Cl  
 CI COM  
 LC STN Files: AGRICOLA, BEILSTEIN\*, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DETHERM\*, EMBASE, GMELIN\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, NIOSHTIC, PIRA, PROMT, RTECS\*, TOXCENTER, ULIDAT, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 DT.CA Caplus document type: Conference; Journal; Patent; Report  
 RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)  
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)  
 RLD.NP Roles for non-specific derivatives from non-patents: PREP (Preparation); PROC (Process); USES (Uses)  
 CRN (24655-84-3)



● Cl<sup>-</sup>

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

695 REFERENCES IN FILE CA (1907 TO DATE)  
 106 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 695 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 50 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> E "THPC"/CN 25

E1 1 THP-ADRIAMYCIN HCL/CN  
 E2 1 THP-M/CN  
 E3 1 --> THPC/CN  
 E4 1 THPE/CN  
 E5 1 THPO/CN  
 E6 1 THPO PROTEIN (MOUSE STRAIN FVB/N CLONE MGC:6080 IMAGE:3593885)/CN  
 E7 1 THPOH/CN  
 E8 1 THPOH, POLYMER WITH 1,2-ETHANEDIAMINE/CN  
 E9 1 THPOH, POLYMER WITH 1,3-DICHLORO-2-PROPANOL AND UREA/CN  
 E10 1 THPOH, POLYMER WITH 1,6-HEXANEDIAMINE/CN  
 E11 1 THPOH, POLYMER WITH 3-BROMOPHENOL, 1,2-ETHANEDIAMINE AND FORMALDEHYDE/CN  
 E12 1 THPOH, POLYMER WITH 4-BROMOPHENOL, 1,2-ETHANEDIAMINE, FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT) AND TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E13 1 THPOH, POLYMER WITH 4-BROMOPHENOL, 1,2-ETHANEDIAMINE, FORMALDEHYDE, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM ACETATE (SALT), TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM HYDROXIDE AND TETRAKIS(HYDROXYMETHYL)PHOSPHONI/CN  
 E14 1 THPOH, POLYMER WITH AMMONIA/CN

E15 1 THPOH, POLYMER WITH AMMONIA, 3-BROMOPHENOL AND FORMALDEHYDE/CN  
 E16 1 THPOH, POLYMER WITH AMMONIA, 3-BROMOPHENOL, FORMALDEHYDE,  
 TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E17 1 THPOH, POLYMER WITH AMMONIA, FORMALDEHYDE AND PHENOL/CN  
 E18 1 THPOH, POLYMER WITH AMMONIA, FORMALDEHYDE, PHENOL,  
 TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E19 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE ((NH4)(OH)),  
 3-BROMOPHENOL, FORMALDEHYDE, TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E20 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE ((NH4)(OH)),  
 FORMALDEHYDE, PHENOL, TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E21 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE, 3-BROMOPHENOL,  
 FORMALDEHYDE, TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E22 1 THPOH, POLYMER WITH AMMONIUM HYDROXIDE, FORMALDEHYDE, PHENOL,  
 TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM ACETATE (SALT) AND  
 TETRAKIS (HYDROXYMETHYL) PHOSPHONIUM PHOSPHATE (1:1) (SALT)/CN  
 E23 1 THPOH, POLYMER WITH FORMALDEHYDE, PHENOL AND  
 1,3,5,7-TETRAAZATRICYCLO(3.3.1.1<sup>3,7</sup>)DECANE/CN  
 E24 1 THPOH, POLYMER WITH UREA/CN  
 E25 1 THPOH-NH3/CN

=> E "FOSCAN"/CN 25

E1 1 FOSBROM/CN  
 E2 1 FOSCAMET/CN  
 E3 1 --> FOSCAN/CN  
 E4 1 FOSCARB/CN  
 E5 1 FOSCARBOXIN/CN  
 E6 1 FOSCARNET/CN  
 E7 1 FOSCARNET SODIUM/CN  
 E8 1 FOSCAVIR/CN  
 E9 1 FOSCHLOR/CN  
 E10 1 FOSCHLOR 50/CN  
 E11 1 FOSCHLOR R/CN  
 E12 1 FOSCHLOR R 50/CN  
 E13 1 FOSCO 715/CN  
 E14 1 FOSCOLIC ACID/CN  
 E15 1 FOSDIOL/CN  
 E16 1 FOSDIOL A/CN  
 E17 1 FOSDIOL, POLYMER WITH 1,3-DIISOCYANATOMETHYLBENZENE, GUANIDINE  
 AND POLYMETHYLENEPOLYPHENYLENE ISOCYANATE/CN  
 E18 1 FOSDIOL, POLYMER WITH 1,3-DIISOCYANATOMETHYLBENZENE,  
 POLYMETHYLENEPOLYPHENYLENE ISOCYANATE AND THIOUREA/CN  
 E19 1 FOSDIOL, POLYMER WITH 1,3-DIISOCYANATOMETHYLBENZENE,  
 POLYMETHYLENEPOLYPHENYLENE ISOCYANATE AND UREA/CN  
 E20 1 FOSDIOL, POLYMER WITH ACETAMIDE, 1,3-DIISOCYANATOMETHYLBENZENE  
 AND POLYMETHYLENEPOLYPHENYLENE ISOCYANATE/CN  
 E21 1 FOSDIOL, POLYMER WITH CYANO GUANIDINE,  
 1,3-DIISOCYANATOMETHYLBENZENE AND POLYMETHYLENEPOLYPHENYLENE ISOCYANATE/CN  
 E22 1 FOSDIOL-GUANIDINE-POLYMETHYLENEPOLYPHENYLENE ISOCYANATE-TDI  
 COPOLYMER/CN  
 E23 1 FOSDIOL-POLYMETHYLENEPOLYPHENYLENEISOCYANATE-TDI-THIOUREA  
 COPOLYMER/CN  
 E24 1 FOSDRIN/CN  
 E25 1 FOSECO/CN

=> S E3

L2 1 FOSCAN/CN

=> DIS L2 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 122341-38-2 REGISTRY

CN Phenol, 3,3',3'',3'''-(7,8-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3,3',3'',3'''-(7,8-Dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol

CN 5,10,15,20-Tetra(m-hydroxyphenyl)chlorin

CN 5,10,15,20-Tetrakis(m-hydroxyphenyl)chlorin

CN 8-Dihydroporphyrin-5

CN EF 9

CN Foscan

CN mTHPC

CN Temoporfin

DR 851449-56-4

MF C44 H32 N4 O4

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CIN, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK\*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: WHO


DT.CA Caplus document type: Conference; Dissertation; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)



=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
14.17	14.38

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 14:15:49 ON 29 NOV 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2005 VOL 143 ISS 23  
FILE LAST UPDATED: 28 Nov 2005 (20051128/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l2  
L3 282 L2

=> s l3 (L) antibod?  
447951 ANTIBOD?  
L4 2 L3 (L) ANTIBOD?

=> d ibib 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:747646 CAPLUS  
DOCUMENT NUMBER: 135:285081  
TITLE: Photodynamic therapy compounds  
INVENTOR(S): Vrouwenraets, Martinus Bernardus; Stigter, Marijke; Snow, Gordon Brian; Van Dongen, Augustinus Antonius Maria Silverster; Postmus, Pieter Edsge; Visser, Gerardus Wilhelmus Maria; Stewart, Fiona Anne; Oppelaar, Hugo  
PATENT ASSIGNEE(S): Neth.  
SOURCE: PCT Int. Appl., 42 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074398	A1	20011011	WO 2000-GB1215	20000330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2376001 AA 20011011 CA 2000-2376001 20000330  
PRIORITY APPLN. INFO.: WO 2000-GB1215 W 20000330  
OTHER SOURCE(S): MARPAT 135:285081  
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1999:241777 CAPLUS  
DOCUMENT NUMBER: 131:41580  
TITLE: Development of meta-tetrahydroxyphenylchlorin-  
monoclonal antibody conjugates for photoimmunotherapy  
AUTHOR(S): Vrouwenraets, Maarten B.; Visser, Gerard W. M.;  
Stewart, Fiona A.; Stigter, Marijke; Oppelaar, Hugo;  
Postmus, Pieter E.; Snow, Gordon B.; van Dongen, Guus  
A. M. S.  
CORPORATE SOURCE: Departments of Otolaryngology/Head and Neck Surgery,  
Free University Hospital, Amsterdam, 1081 HV, Neth.  
SOURCE: Cancer Research (1999), 59(7), 1505-1513  
CODEN: CNREA8; ISSN: 0008-5472  
PUBLISHER: AACR Subscription Office  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s antibod  
L5 22 ANTIBOD

=> s antibod?  
L6 447951 ANTIBOD?

=> s 16 and 13  
L7 13 L6 AND L3

=> s 17 not py>1999  
6119825 PY>1999  
L8 2 L7 NOT PY>1999

=> d ibib 1-2

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1999:241777 CAPLUS  
DOCUMENT NUMBER: 131:41580  
TITLE: Development of meta-tetrahydroxyphenylchlorin-  
monoclonal antibody conjugates for  
photoimmunotherapy  
AUTHOR(S): Vrouwenraets, Maarten B.; Visser, Gerard W. M.;  
Stewart, Fiona A.; Stigter, Marijke; Oppelaar, Hugo;  
Postmus, Pieter E.; Snow, Gordon B.; van Dongen, Guus  
A. M. S.  
CORPORATE SOURCE: Departments of Otolaryngology/Head and Neck Surgery,  
Free University Hospital, Amsterdam, 1081 HV, Neth.  
SOURCE: Cancer Research (1999), 59(7), 1505-1513  
CODEN: CNREA8; ISSN: 0008-5472  
PUBLISHER: AACR Subscription Office  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1998:370899 CAPLUS  
 DOCUMENT NUMBER: 129:133195  
 TITLE: Selective accumulation of meso-tetra(hydroxyphenyl)chlorin in steroid-synthesizing cells of the rat adrenal gland  
 AUTHOR(S): Colombo-Benkmann, Mario; Muhm, Markus; Gahlen, Johannes; Vry, Magnus-Sebastian; Deubzer, Hedwig; Holloschi, Andreas; Hafner, Matthias; Heym, Christine; Senninger, Norbert  
 CORPORATE SOURCE: Dept. of Surgery, Univ. of Heidelberg, Heidelberg, 69120, Germany  
 SOURCE: Proceedings of SPIE-The International Society for Optical Engineering (1998), 3260(Optical Investigations of Cells in Vitro and in Vivo), 136-140  
 CODEN: PSISDG; ISSN: 0277-786X  
 PUBLISHER: SPIE-The International Society for Optical Engineering  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs 2

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1998:370899 CAPLUS  
 DOCUMENT NUMBER: 129:133195  
 TITLE: Selective accumulation of meso-tetra(hydroxyphenyl)chlorin in steroid-synthesizing cells of the rat adrenal gland  
 AUTHOR(S): Colombo-Benkmann, Mario; Muhm, Markus; Gahlen, Johannes; Vry, Magnus-Sebastian; Deubzer, Hedwig; Holloschi, Andreas; Hafner, Matthias; Heym, Christine; Senninger, Norbert  
 CORPORATE SOURCE: Dept. of Surgery, Univ. of Heidelberg, Heidelberg, 69120, Germany  
 SOURCE: Proceedings of SPIE-The International Society for Optical Engineering (1998), 3260(Optical Investigations of Cells in Vitro and in Vivo), 136-140  
 CODEN: PSISDG; ISSN: 0277-786X  
 PUBLISHER: SPIE-The International Society for Optical Engineering  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Rat adrenal glands fluoresce intensely after systemic application of meso-tetra(hydroxyphenyl)chlorin (m THPC). We investigated which parts of the adrenal gland accumulate mTHPC. Furthermore we examined the time course of adrenal mTHPC-accumulation. Ten male Wistar rats each were given 0.5 or 0.7 mg mTHPC kg<sup>-1</sup> i.v. Each two animals were perfused with normal saline and Zamboni fixative 6, 12, 24, 48 and 72 h after photosensitization. Untreated animals served as controls. Fluorescence was quantified on 20 µm frozen sections with CCD-camera and appropriate software. Immunohistochem. identified specific cell types with antibodies to steroid-synthesizing enzymes. The cortex exhibited an intense fluorescence, with weaker fluorescence of corticocytes in the zona glomerulosa compared to the other zones. Besides intensely fluorescing singly lying scattered cells, the medulla showed a faint mTHPC-induced fluorescence. Immunohistochem. revealed that intramedullary cells with intense fluorescence were corticocytes, showing a pos. reaction to the 21-β-hydroxylase antibody. Peak accumulation of mTHPC was always observed after 24 h. Our results indicate for the first time that only steroid synthesizing cells of the adrenal gland exhibit an intense photosensitizer-induced fluorescence. Thus mTHPC-application is an uncomplicated method to identify steroid-synthesizing cells, possibly

also in other organs.

REFERENCE COUNT: 15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file pctfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

16.41

30.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.73

-0.73

FILE 'PCTFULL' ENTERED AT 14:18:03 ON 29 NOV 2005

COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED: 22 NOV 2005 <20051122/UP>

MOST RECENT UPDATE WEEK: 200546 <200546/EW>

FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> KWIC format free of charge - SEE NEWS >>>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

[http://www.stn-international.de/stndatabases/details/ipc\\_reform.html](http://www.stn-international.de/stndatabases/details/ipc_reform.html) <

=> s ?thpc

L9 94 ?THPC

=> s antibod?

L10 82883 ANTIBOD?

=> s ?porphyrin or ?chlorin

3943 ?PORPHYRIN

511 ?CHLORIN

L11 4116 ?PORPHYRIN OR ?CHLORIN

=> s l11/ab

LEFT TRUNCATION IGNORED FOR '?CHLORIN/A' FOR FILE 'PCTFULL'

LEFT TRUNCATION IGNORED FOR '?CHLORIN' FOR FILE 'PCTFULL'

170 PORPHYRIN/AB

18 CHLORIN/AB

L12 182 (?PORPHYRIN/AB OR ?CHLORIN/AB)

Left truncation is not valid in the specified search field in the  
specified file. The term has been searched without left truncation.

Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'  
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you  
used a truncation symbol after a punctuation mark, the system may  
interpret the truncation symbol as being at the beginning of a term.  
Implied proximity is used in search fields indexed as single words,  
for example, the Basic Index.

=> s (porphyrin or chlorin)/ab

170 PORPHYRIN/AB

81 PORPHYRINS/AB

229 PORPHYRIN/AB

((PORPHYRIN OR PORPHYRINS)/AB)

18 CHLORIN/AB

15 CHLORINS/AB

30 CHLORIN/AB

((CHLORIN OR CHLORINS)/AB)  
L13 242 (PORPHYRIN OR CHLORIN)/AB

=> s 19 and 113  
L14 11 L9 AND L13

=> s 114 and 110  
L15 4 L14 AND L10

=> s 115 and conjugat?  
70662 CONJUGAT?  
L16 4 L15 AND CONJUGAT?

=> s 116 not py>1999  
614766 PY>1999  
L17 1 L16 NOT PY>1999

=> d ibib

L17 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2005 Univentio on STN  
ACCESSION NUMBER: 1998025648 PCTFULL ED 20020514  
TITLE (ENGLISH): USE OF A TEXAPHYRIN IN OCULAR DIAGNOSIS AND THERAPY  
TITLE (FRENCH): UTILISATION DE TEXAPHYRINE DANS LA PREPARATION D'UN  
MEDICAMENT EMPLOYE EN DIAGNOSTIC ET THERAPIE OCULAIRES  
INVENTOR(S): BLUMENKRANZ, Mark, S.;  
WOODBURN, Kathryn, W.;  
MILLER, Richard, A.;  
YOUNG, Stuart, W.  
PATENT ASSIGNEE(S): PHARMACYCLICS, INC.;  
BLUMENKRANZ, Mark, S.;  
WOODBURN, Kathryn, W.;  
MILLER, Richard, A.;  
YOUNG, Stuart, W.  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:  

NUMBER	KIND	DATE
WO 9825648	A2	19980618

  
DESIGNATED STATES  
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE  
ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK  
LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD  
SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM  
KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE  
CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF  
CG CI CM GA GN ML MR NE SN TD TG  
APPLICATION INFO.: WO 1997-US22661 A 19971211  
PRIORITY INFO.: US 1996-08/763,451 19961211

=> d his

(FILE 'HOME' ENTERED AT 14:13:26 ON 29 NOV 2005)

FILE 'REGISTRY' ENTERED AT 14:13:54 ON 29 NOV 2005

E "M-THPC"/CN 25

E "THPC"/CN 25

L1 1 S E3

E "THPC"/CN 25

E "FOSCAN"/CN 25

L2 1 S E3

FILE 'CAPLUS' ENTERED AT 14:15:49 ON 29 NOV 2005

```

L3          282 S L2
L4           2 S L3 (L) ANTIBOD?
L5          22 S ANTIBOD
L6         447951 S ANTIBOD?
L7          13 S L6 AND L3
L8           2 S L7 NOT PY>1999

```

FILE 'PCTFULL' ENTERED AT 14:18:03 ON 29 NOV 2005

```

L9           94 S ?THPC
L10          82883 S ANTIBOD?
L11          4116 S ?PORPHYRIN OR ?CHLORIN
L12          182 S L11/AB
L13          242 S (PORPHYRIN OR CHLORIN)/AB
L14           11 S L9 AND L13
L15           4 S L14 AND L10
L16           4 S L15 AND CONJUGAT?
L17           1 S L16 NOT PY>1999

```

=> s l11 and l10

```

L18          1960 L11 AND L10

```

=> s conjugat? and l18

```

              70662 CONJUGAT?
L19          1515 CONJUGAT? AND L18

```

=> s conjugat? (P) l6

```

              70662 CONJUGAT?
              82883 ANTIBOD?
L20          47135 CONJUGAT? (P) L6

```

=> s l20 and l11

```

L21          1491 L20 AND L11

```

=> s l11/clm

LEFT TRUNCATION IGNORED FOR '?CHLORIN/C' FOR FILE 'PCTFULL'

LEFT TRUNCATION IGNORED FOR '?CHLORIN' FOR FILE 'PCTFULL'

```

              607 PORPHYRIN/CLM
              127 CHLORIN/CLM
L22          665 (?PORPHYRIN/CLM OR ?CHLORIN/CLM)

```

Left truncation is not valid in the specified search field in the specified file. The term has been searched without left truncation. Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID' would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you used a truncation symbol after a punctuation mark, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words, for example, the Basic Index.

=> d his

(FILE 'HOME' ENTERED AT 14:13:26 ON 29 NOV 2005)

FILE 'REGISTRY' ENTERED AT 14:13:54 ON 29 NOV 2005

```

              E "M-THPC"/CN 25
              E "THPC"/CN 25
L1           1 S E3
              E "THPC"/CN 25
              E "FOSCAN"/CN 25
L2           1 S E3

```

FILE 'CAPLUS' ENTERED AT 14:15:49 ON 29 NOV 2005

```

L3           282 S L2

```

L4 2 S L3 (L) ANTIBOD?  
 L5 22 S ANTIBOD  
 L6 447951 S ANTIBOD?  
 L7 13 S L6 AND L3  
 L8 2 S L7 NOT PY>1999

FILE 'PCTFULL' ENTERED AT 14:18:03 ON 29 NOV 2005

L9 94 S ?THPC  
 L10 82883 S ANTIBOD?  
 L11 4116 S ?PORPHYRIN OR ?CHLORIN  
 L12 182 S L11/AB  
 L13 242 S (PORPHYRIN OR CHLORIN)/AB  
 L14 11 S L9 AND L13  
 L15 4 S L14 AND L10  
 L16 4 S L15 AND CONJUGAT?  
 L17 1 S L16 NOT PY>1999  
 L18 1960 S L11 AND L10  
 L19 1515 S CONJUGAT? AND L18  
 L20 47135 S CONJUGAT? (P) L6  
 L21 1491 S L20 AND L11  
 L22 665 S L11/CLM

=> s l21 not py>1999  
 614766 PY>1999  
 L23 321 L21 NOT PY>1999

=> s conjugat? (P) l10  
 70662 CONJUGAT?  
 L24 47135 CONJUGAT? (P) L10

=> s l11 (P) conjugat?  
 70662 CONJUGAT?  
 L25 1919 L11 (P) CONJUGAT?

=> s l25 and l24  
 L26 1403 L25 AND L24

=> s l26 and l9  
 L27 20 L26 AND L9

=> s l27 not py>1999  
 614766 PY>1999  
 L28 2 L27 NOT PY>1999

=> d ibib 1-2

L28 ANSWER 1 OF 2 PCTFULL COPYRIGHT 2005 Univentio on STN  
 ACCESSION NUMBER: 1998052609 PCTFULL ED 20020514  
 TITLE (ENGLISH): SONODYNAMIC THERAPY USING AN ULTRASOUND SENSITIZER  
 COMPOUND  
 TITLE (FRENCH): THERAPIE SONODYNAMIQUE METTANT EN OEUVRE UN COMPOSE  
 SENSIBILISANT ULTRASONORE  
 INVENTOR(S): ALFHEIM, Jan, Alan;  
 HENRICHS, Paul, Mark;  
 HOHENSCHUH, Eric, Paul;  
 JOHANNESSEN, Edvin, Wilhelm;  
 SANDERSON, William, Anthony;  
 SNOW, Robert, Allen  
 PATENT ASSIGNEE(S): NYCOMED IMAGING AS;  
 ALFHEIM, Jan, Alan;  
 HENRICHS, Paul, Mark;  
 HOHENSCHUH, Eric, Paul;  
 JOHANNESSEN, Edvin, Wilhelm;  
 SANDERSON, William, Anthony;

LANGUAGE OF PUBL.: SNOW, Robert, Allen  
DOCUMENT TYPE: English  
PATENT INFORMATION: Patent

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 9852609	A1	19981126
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-GB1444	A	19980519
PRIORITY INFO.:	GB 1997-9710049.9		19970519

L28 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2005 Univentio on STN  
ACCESSION NUMBER: 1998025648 PCTFULL ED 20020514  
TITLE (ENGLISH): USE OF A TEXAPHYRIN IN OCULAR DIAGNOSIS AND THERAPY  
TITLE (FRENCH): UTILISATION DE TEXAPHYRINE DANS LA PREPARATION D'UN  
MEDICAMENT EMPLOYE EN DIAGNOSTIC ET THERAPIE OCULAIRES  
INVENTOR(S): BLUMENKRANZ, Mark, S.;  
WOODBURN, Kathryn, W.;  
MILLER, Richard, A.;  
YOUNG, Stuart, W.  
PATENT ASSIGNEE(S): PHARMACYCLICS, INC.;  
BLUMENKRANZ, Mark, S.;  
WOODBURN, Kathryn, W.;  
MILLER, Richard, A.;  
YOUNG, Stuart, W.  
LANGUAGE OF PUBL.: English  
DOCUMENT TYPE: Patent  
PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 9825648	A2	19980618
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-US22661	A	19971211
PRIORITY INFO.:	US 1996-08/763,451		19961211

=> d kwic 2

L28 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2005 Univentio on STN

DETD 0 Photodynamic therapy of conditions in the eye characterized by neovascularization has been attempted using conventional porphyrin derivatives such as hematoporphyrin derivative (dihematoporphyrin ether), PHOTOFRIN<sup>®</sup>; porfimer sodium, and tin ethyl etiopurpurin. Problems have been encountered in this context due to interference from eye pigments, as described in U.S. Patent 5,576,013 to Williams, et al. for example. In addition, phthalocyanine and

benzoporphyrin derivatives have been used in photodynamic treatment. PCT publication WO 95/24930 and Miller et al.,

(Archives of Ophthalmology, June, 1995) relate to treatment of eye conditions

characterized by unwanted neovasculature comprising administering a green porphyrin

to the neovasculature and irradiating the neovasculature with light having a wavelength

of 550-695 nm. U.S. Patents 5,166,197 and 5,484,778 relate. . .

sodium

(PHOTOFRIN<sup>®</sup>, requiring light of 630 nm and causing cutaneous photosensitivity that

may last for up to 6 weeks), and benzoporphyrin derivative

(BPD verteporfin, causing cutaneous photosensitivity of a few days). Lin et al. (IOVS 34:1303 Abstract 2953,

1993) relate to the photodynamic occlusion of choroidal vessels using benzoporphyrin

derivative BPD-MA. Bauman et al. (Invest. Ophthalmol. Vis. Sci.

37/3:S122 (abstract)

1996) relates to PDT of experimental choroidal neovascularization with.

an advantage in the ocular methods of

use provided herein, providing for rapid infusion as a bolus as compared to BPD,

mTHPC, or SnET2 which require solubilizing vehicles such as lipid environments, for

example; and further obviating the need for a lipophilic. . .

#### ABBREVIATIONS

ARMD Age related macular degeneration

7

BPD - Benzoporphyrin derivative

IN - Inferonasal

IT Inferotemporal

CNV (M) Choroidal neovascularization (membrane)

FWHM - full width half maximum

HDL - high-density lipoproteins

ICG indocyanine green

LDL Low density lipoprotein

Lu(III)T2BET - lutetium texaphyrin, T2BET

mTHPC Tetra(m-hydroxyphenyl)chlorin

NZW New Zealand White

OD Right eye

OS Left eye

PDT Photodynamic therapy

SN Superonasal

SnET2 - Tin etiopurpurin

ST Superotemporal

TGF-b - Transforming growth factor-b

Txp Texaphyrin

0 VEGF. . .

In an embodiment of the present invention, texaphyrins are further coupled to

site-directing molecules to form conjugates for targeted in

vivo delivery. "Site-

directing" means having specificity for targeted sites. "Specificity for targeted sites"

means that upon contacting the texaphyrin-conjugate with the targeted site, for example,

5 under physiological conditions of ionic strength, temperature, pH and the like, specific binding will occur. The interaction may occur due to specific electrostatic, hydrophobic, entropic or other interaction of certain residues of the conjugate with specific residues of the target to form a stable complex under conditions effective to promote the interaction. A site-directing. . . limited to: lipoproteins including low density lipoprotein; cholesterol; polyamides including peptides having affinity for an ocular receptor; proteins such as antibodies or an immunologically active fragment thereof;

15  
oligonucleotides complementary to an ocular DNA or RNA; histamine; hormone  
mimics such as morphine; a. . .

derivatives of amino acids like; derivatives thereof; and texaphyrin metal complexes. The term "appended to the texaphyrin complex-site directing molecule conjugate" means that the catalytic groups are attached either directly to the texaphyrin metal complex or to the texaphyrin complex via a linker or couple of variable length, or are attached to the ligand portion of a texaphyrin complex-ligand conjugate either with or without a linker or couple of variable length

the lipoprotein phase of the blood, LDL is expected to more efficiently deliver texaphyrin to the target tissue. A texaphyrin-LDL conjugate is selective for neovascularization since leakage of the conjugate is expected to occur only in neovasculature due to the large size of the conjugate. LDL can be isolated and purified according to the procedure of Havel et al., (J. Clin. Invest., 34:1345, 1995)

In most preferred embodiments, conjugates and appended groups are covalently bonded to the texaphyrin via a carbon-carbon, carbon-nitrogen, carbon-sulfur, or a carbon-oxygen bond, more preferably a. . .

Treatment of carboxylated texaphyrins with thionyl chloride or p-nitrophenol acetate would generate activated acyl species suitable for attachment to monoclonal antibodies or other biomolecules of interest. Standard in situ coupling methods (e.g., 1,1'-carbonyldiimidazole) could be used to effect the conjugation

=> d his

(FILE 'HOME' ENTERED AT 14:13:26 ON 29 NOV 2005)

FILE 'REGISTRY' ENTERED AT 14:13:54 ON 29 NOV 2005  
E "M-THPC"/CN 25



L1           E "THPC"/CN 25  
           1 S E3  
           E "THPC"/CN 25  
           E "FOSCAN"/CN 25  
 L2           1 S E3

FILE 'CAPLUS' ENTERED AT 14:15:49 ON 29 NOV 2005

L3           282 S L2  
 L4           2 S L3 (L) ANTIBOD?  
 L5           22 S ANTIBOD  
 L6           447951 S ANTIBOD?  
 L7           13 S L6 AND L3  
 L8           2 S L7 NOT PY>1999

FILE 'PCTFULL' ENTERED AT 14:18:03 ON 29 NOV 2005

L9           94 S ?THPC  
 L10          82883 S ANTIBOD?  
 L11          4116 S ?PORPHYRIN OR ?CHLORIN  
 L12          182 S L11/AB  
 L13          242 S (PORPHYRIN OR CHLORIN)/AB  
 L14          11 S L9 AND L13  
 L15          4 S L14 AND L10  
 L16          4 S L15 AND CONJUGAT?  
 L17          1 S L16 NOT PY>1999  
 L18          1960 S L11 AND L10  
 L19          1515 S CONJUGAT? AND L18  
 L20          47135 S CONJUGAT? (P) L6  
 L21          1491 S L20 AND L11  
 L22          665 S L11/CLM  
 L23          321 S L21 NOT PY>1999  
 L24          47135 S CONJUGAT? (P) L10  
 L25          1919 S L11 (P) CONJUGAT?  
 L26          1403 S L25 AND L24  
 L27          20 S L26 AND L9  
 L28          2 S L27 NOT PY>1999

=> s cancer? or tumor? or neoplas?  
           73267 CANCER?  
           61391 TUMOR?  
           21140 NEOPLAS?  
 L29        91450 CANCER? OR TUMOR? OR NEOPLAS?

=> s l24 and l11  
 L30        1491 L24 AND L11

=> s l30 and l29  
 L31        1287 L30 AND L29

=> s l31 and l9  
 L32        20 L31 AND L9

=> s l32 not py>1999  
           614766 PY>1999  
 L33        2 L32 NOT PY>1999

=> d ibib 1-2

L33    ANSWER 1 OF 2           PCTFULL    COPYRIGHT 2005 Univentio on STN  
 ACCESSION NUMBER:           1998052609 PCTFULL   ED 20020514  
 TITLE (ENGLISH):           SONODYNAMIC THERAPY USING AN ULTRASOUND SENSITIZER  
                               COMPOUND  
 TITLE (FRENCH):            THERAPIE SONODYNAMIQUE METTANT EN OEUVRE UN COMPOSE  
                               SENSIBILISANT ULTRASONORE  
 INVENTOR(S):                ALFHEIM, Jan, Alan;

HENRICHS, Paul, Mark;  
 HOHENSCHUH, Eric, Paul;  
 JOHANNESSEN, Edvin, Wilhelm;  
 SANDERSON, William, Anthony;  
 SNOW, Robert, Allen  
 PATENT ASSIGNEE(S): NYCOMED IMAGING AS;  
 ALFHEIM, Jan, Alan;  
 HENRICHS, Paul, Mark;  
 HOHENSCHUH, Eric, Paul;  
 JOHANNESSEN, Edvin, Wilhelm;  
 SANDERSON, William, Anthony;  
 SNOW, Robert, Allen  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9852609	A1	19981126
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1998-GB1444	A	19980519
PRIORITY INFO.:	GB 1997-9710049.9		19970519

L33 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2005 Univentio on STN  
 ACCESSION NUMBER: 1998025648 PCTFULL ED 20020514  
 TITLE (ENGLISH): USE OF A TEXAPHYRIN IN OCULAR DIAGNOSIS AND THERAPY  
 TITLE (FRENCH): UTILISATION DE TEXAPHYRINE DANS LA PREPARATION D'UN  
 MEDICAMENT EMPLOYE EN DIAGNOSTIC ET THERAPIE OCULAIRES  
 INVENTOR(S): BLUMENKRANZ, Mark, S.;  
 WOODBURN, Kathryn, W.;  
 MILLER, Richard, A.;  
 YOUNG, Stuart, W.  
 PATENT ASSIGNEE(S): PHARMACYCLICS, INC.;  
 BLUMENKRANZ, Mark, S.;  
 WOODBURN, Kathryn, W.;  
 MILLER, Richard, A.;  
 YOUNG, Stuart, W.  
 LANGUAGE OF PUBL.: English  
 DOCUMENT TYPE: Patent  
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9825648	A2	19980618
DESIGNATED STATES	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG		
APPLICATION INFO.:	WO 1997-US22661	A	19971211
PRIORITY INFO.:	US 1996-08/763,451		19961211

=> d kwic 2

L33 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2005 Univentio on STN

DETD 0 Photodynamic therapy of conditions in the eye characterized by neovascularization has been attempted using conventional porphyrin derivatives such as hematoporphyrin derivative (di-hematoporphyrin ether), PHOTOFRIN<sup>®</sup>; porfimer sodium, and tin ethyl etiopurpurin. Problems have been encountered in this context due to interference from eye pigments, as described in U.S. Patent 5,576,013 to Williams, et al. for example. In addition, phthalocyanine and benzoporphyrin derivatives have been used in photodynamic treatment. PCT publication WO 95/24930 and Miller et al., (Archives of Ophthalmology, June, 1995) relate to treatment of eye conditions characterized by unwanted neovasculature comprising administering a green porphyrin to the neovasculature and irradiating the neovasculature with light having a wavelength of 550-695 nm. U.S. Patents 5,166,197 and 5,484,778 relate. . .

sodium (PHOTOFRIN<sup>®</sup>;, requiring light of 630 nm and causing cutaneous photosensitivity that may last for up to 6 weeks), and benzoporphyrin derivative (BPD verteporfin, causing cutaneous photosensitivity of a few days). Lin et al. (IOVS 34:1303 Abstract 2953, 1993) relate to the photodynamic occlusion of choroidal vessels using benzoporphyrin derivative BPD-MA. Bauman et al. (Invest. Ophthalmol. Vis. Sci. 37/3:S122 (abstract) 1996) relates to PDT of experimental choroidal neovascularization with. . .

range, and they exhibit inherent selective uptake or biolocalization in certain tissues, particularly regions such as, for example, liver, atheroma or tumor tissue. Texaphyrins have exhibited significant tumor selectivity as detected by magnetic resonance imaging and fluorescence detection. Texaphyrins and water-soluble texaphyrins, method of preparation and various uses. . .

an advantage in the ocular methods of use provided herein, providing for rapid infusion as a bolus as compared to BPD,

mTHPC, or SnET2 which require solubilizing vehicles such as lipid environments, for example; and further obviating the need for a lipophilic. . .

#### ABBREVIATIONS

ARMD		Age related macular degeneration
7		
BPD	-	Benzoporphyrin derivative
IN	-	Inferonasal
IT		Inferotemporal
CNV (M)		Choroidal neovascularization (membrane)
FWHM	-	full width half maximum
HDL	-	high-density lipoproteins
ICG		indocyanine green
LDL		Low density lipoprotein

Lu(III)T2BET - lutetium texaphyrin, T2BET  
                   mTHPC                   Tetra(m-hydroxyphenyl)chlorin  
 NZW                   New Zealand White  
 OD                   Right eye  
 OS                   Left eye  
 PDT                   Photodynamic therapy  
 SN                   Superonasal  
 SnET2 -           Tin etiopurpurin  
 ST                   Superotemporal  
 TGF-b -           Transforming growth factor-b  
 Txp                   Texaphyrin  
 0           VEGF. . .

. . .  
 retinal or choroidal neovasculature, ocular histoplasmosis syndrome,  
 myopia,

9

ocular inflammatory diseases, central serous retinopathy, subretinal  
 neovascular  
 membrane, or neovasculature induced by neoplasm, such as  
 melanoma or retinal  
 blastoma, for example. Treatment of abnormal vasculature related to  
 pigmented and  
 nonpigmented ocular cancers, including melanoma is also  
 contemplated in the use of  
 the present invention. Ocular melanoma includes uveal melanoma, and  
 melanoma of  
 the. . .

In an embodiment of the present invention, texaphyrins are further  
 coupled to  
 site-directing molecules to form conjugates for targeted in  
 vivo delivery. "Site-  
 directing" means having specificity for targeted sites. "Specificity for  
 targeted sites"  
 means that upon contacting the texaphyrin-conjugate with the  
 targeted site, for example,  
 5 under physiological conditions of ionic strength, temperature, pH and  
 the like, specific  
 binding will occur. The interaction may occur due to specific  
 electrostatic,  
 hydrophobic, entropic or other interaction of certain residues of the  
 conjugate with  
 specific residues of the target to form a stable complex under  
 conditions effective to  
 promote the interaction. A site-directing. . . limited to:  
 lipoproteins including low density  
 lipoprotein; cholesterol; polyamides including peptides having affinity  
 for an ocular  
 receptor; proteins such as antibodies or an immunologically  
 active fragment thereof;  
 15  
 oligonucleotides complementary to an ocular DNA or RNA; histamine;  
 hormone  
 mimics such as morphine; a. . .

. . .  
 derivatives of amino acids  
 like; derivatives thereof; and texaphyrin metal complexes. The term  
 "appended to the  
 texaphyrin complex-site directing molecule conjugate" means  
 that the catalytic groups  
 are attached either directly to the texaphyrin metal complex or to the  
 texaphyrin  
 complex via a linker or couple of variable length, or are attached to  
 the ligand portion o

0 a texaphyrin complex-ligand conjugate either with or without a linker or couple of variable length

. . . the lipoprotein phase of the blood, LDL is expected to more efficiently deliver texaphyrin to the target tissue. A texaphyrin-LDL conjugate is selective for neovascularization since leakage of the conjugate is expected to occur only in neovasculature due to the large size of the conjugate. LDL can be isolated and purified 0 according to the procedure of Haul et al., (J. Clin. Invest., 34:1345, 1995)

In most preferred embodiments, conjugates and appended groups are covalently bonded to the texaphyrin via a carbon-carbon, carbon-nitrogen, carbon-sulfur, or a carbon-oxygen bond, more preferably a. . .

. . . Treatment of carboxylated texaphyrins with thionyl chloride or p-nitrophenol acetate would generate activated acyl species suitable for attachment to monoclonal 5 antibodies or other biomolecules of interest. Standard in situ coupling methods (e.g., 1,1'-carbonyldiimidazole) could be used to effect the conjugation

CLMEN. . . neovasculature, choroidal neovasculature, ocular histoplasmosis syndrome, myopia, ocular inflammatory disease, central serous retinopathy, subretinal neovascular membrane, and neovasculature induced by neoplasm.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	27.15	57.94
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.73

STN INTERNATIONAL LOGOFF AT 14:31:05 ON 29 NOV 2005

Connecting via Winsock to STN